- Conditions
- ECMO, Heparin, Respiratory Failure
- Interventions
- subcutaneous heparin anticoagulation
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–19
of 19
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Kidney Injury, Acute Renal Failure, Heart Failure
- Interventions
- Dilute unfractionated heparin, Standard concentration unfractionated heparin
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Deep Venous Thrombosis
- Interventions
- Thrombolysis/Thrombectomy
- Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Extracorporeal Membrane Oxygenation Complication, Anticoagulants
- Interventions
- Bivalirudin, Unfractionated heparin
- Drug
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Stroke, Atrial Fibrillation, Embolism
- Interventions
- warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 21,105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 316
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
- Conditions
- Pulmonary Embolism, Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- Catheter directed therapy, Systemic anticoagulation
- Device · Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, REGN9933, Apixaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Fairhope, Alabama • Covina, California + 36 more
- Conditions
- Sars-CoV2, COVID
- Interventions
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 6
- States / cities
- Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
- Conditions
- Lymphoma, Acute Lymphoblastic Leukemia
- Interventions
- Apixaban, No systemic anticoagulant prophylaxis
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, REGN9933, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 18
- States / cities
- Dothan, Alabama • Fremont, California • Huntington Beach, California + 15 more
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Acute
- Interventions
- Left Atrial Appendage Occlusion
- Other
- Lead sponsor
- Kansas City Heart Rhythm Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Atrial Fibrillation
- Interventions
- Patient Decision Support Tool
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Atrial Fibrillation
- Interventions
- AFSW Guided DOAC, Continuous DOAC therapy
- Device · Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 22 Years to 85 Years
- Enrollment
- 5,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 93
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more
- Conditions
- Antiphospholipid Antibody Syndrome, End Stage Renal Disease
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Atrial Fibrillation, Hypertension
- Interventions
- catheter ablation, renal sympathetic denervation
- Procedure
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Short Hills, New Jersey
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Venous Thromboembolism
- Interventions
- vMetrics protocol
- Other
- Lead sponsor
- ZIN Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Stroke, Hyperglycemia, Procoagulation Markers
- Interventions
- Glycemic Control
- Other
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Long Beach, California • Los Angeles, California + 26 more
- Conditions
- Stroke
- Interventions
- Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
- Device
- Lead sponsor
- Coherex Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 18 more